3 Absurdly Cheap Growth Stocks to Buy in May 2026

The article highlights Novo Nordisk, PDD Holdings, and Intuit as low-multiple growth stocks, citing forward P/Es of 13, 8, and 15, respectively. Novo Nordisk faces competition and expected revenue decline this year, PDD is pressured by tariffs and trade uncertainty, and Intuit is weighed down by AI-related software concerns despite 17% revenue growth in its latest quarter. Overall, it is a valuation-focused opinion piece rather than new company-specific fundamental news.

Analysis

This is less a generic “cheap stocks” piece than a dispersion signal: the market is punishing three very different types of uncertainty—competitive disruption in healthcare, policy/friction risk in cross-border commerce, and AI-fear multiple compression in software. That setup tends to create asymmetric returns if fundamentals merely stabilize, because valuation already discounts a meaningful amount of bad news; the hurdle is no longer growth acceleration, but avoiding further de-rating over the next 1-2 quarters.

INTU stands out as the cleanest second-order winner. If AI is commoditizing lower-end software, trusted, compliance-heavy workflows should actually consolidate around incumbents with embedded data, distribution, and switching costs; the real threat is not replacement but margin pressure from heavier AI spend. That makes the risk/reward more about execution than existential disruption, and a rerating can happen quickly if management shows AI is additive to ARPU and retention rather than dilutive.

NVO and PDD are both deeper-value situations but with different clocks. NVO likely needs months, not days: the market wants evidence that product mix, pricing, and capacity can offset share loss, and any improvement in prescription trends or a cleaner CEO narrative could drive a sharp multiple rebound from depressed levels. PDD is more binary and policy-driven; tariff headlines can overwhelm operating progress near term, but if Temu maintains user engagement and supply chain routing adapts, the stock’s low multiple leaves room for a reflexive rally on even modestly better cross-border visibility.

The consensus is missing that these are not all the same trade. INTU is a quality compounder temporarily de-rated; NVO is a franchise under strategic scrutiny; PDD is a geopolitically levered consumer platform with optionality but lower visibility. The best opportunities are likely in buying durability where the market is pricing disruption, while demanding a much wider margin of safety for names exposed to policy and competitive uncertainty.

Key Decisions for Investors

• Long INTU on a 3-6 month horizon; use weakness below recent trading ranges to build. Risk/reward is attractive if management confirms AI is accretive to retention and monetization, with a path to multiple expansion back toward premium software peers.
• Initiate a tactical pair: long INTU / short a basket of lower-moat software names most exposed to AI replacement risk over the next 1-2 quarters. The spread benefits if the market continues to distinguish trusted workflow software from commoditized point solutions.
• For NVO, prefer staged entry over 2-3 months rather than full position now. Use it as a mean-reversion trade only if prescription/launch commentary stops deteriorating; stop out if competitive share loss persists through the next two reporting cycles.
• For PDD, keep sizing smaller and treat as event-driven optionality. Consider a long position only if trade/tariff noise fades; otherwise, hedge with broader China consumer exposure or use call spreads to cap downside from policy shocks.
• If seeking asymmetric upside, buy INTU call spreads 6-9 months out rather than outright equity. The thesis is rerating from fear reversal, so defined-risk options better match the catalyst window and limit theta drag while waiting for sentiment to normalize.